Your Messages Inbox
Your Article Summary
See Latest ArticlesIndependent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
Journal of Clinical Oncology, 09/04/09
Gray R et al. – The risk of progression was reduced by more than half and the ORR more than doubled with the addition of bevacizumab to weekly paclitaxel in both analyses, confirming a substantial and robust bevacizumab treatment effect. The consistency between the IRF and ECOG analyses validates the original data previously reported by ECOG in this open–label trial.
Related Articles
Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies
Journal of Cancer Research & Clinical Oncology, 11/17/09
Relevance Score: 91%
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 91%
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
Journal of Clinical Oncology, 10/22/09
Relevance Score: 89%
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501
Journal of Clinical Oncology, 10/15/09
Relevance Score: 89%
Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion
Eye, 10/06/09
Relevance Score: 89%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor